m+Medelevator.RU
← Поиск публикаций
Frontiers in cardiovascular medicine · 2026

The influence of C-reactive protein-triglyceride-glucose index (CTI) on the prognosis of heart failure patients with different ejection fractions.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Ma Xinuo, Wang Feng, Liu Dajin, Li Ying, Xia Ping, Xu Yunyun, Xia Han, Peng Yujuan, Chen Lixing

Аннотация

OBJECTIVE: The C-reactive protein-triglyceride-glucose index (CTI) is a novel biomarker integrating inflammation and insulin resistance. Its prognostic value for all-cause mortality in patients with chronic heart failure (CHF) across the ejection fraction (EF) spectrum remains unclear.

METHODS: Patients were categorized into low- and high-CTI groups based on a restricted cubic spline-derived cutoff. Kaplan-Meier curves were used to compare survival, and Cox proportional hazards models were used to assess the association between CTI and all-cause mortality. Receiver operating characteristic (ROC) analysis and subgroup analyses were performed.

RESULTS: A total of 1,130 patients with CHF were included. Kaplan-Meier survival analysis showed that patients with elevated CTI levels had a significantly higher risk of all-cause mortality compared to those with lower CTI levels. Multivariable-adjusted Cox proportional hazards analysis further confirmed that CTI levels were independently associated with increased all-cause mortality. Subgroup analysis demonstrated that elevated CTI levels were associated with higher all-cause mortality in patients with heart failure with reduced ejection fraction (HFrEF) and mildly reduced ejection fraction (HFmrEF).

CONCLUSIONS: CTI is an independent prognostic marker for all-cause mortality in patients with CHF across different EF subtypes and may serve as a useful risk stratification biomarker.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты